List of Figures
Figure 3.1 Stem Cell Therapies: Process of Therapy Development and Administration
Figure 3.2 Classification of Stem Cell Therapies by Type of Cells
Figure 3.3 Potential Application Areas for Stem Cell Therapies
Figure 4.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Therapeutic Area
Figure 4.2 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Phase of Development
Figure 4.3 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells
Figure 4.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells
Figure 4.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Stem Cell Lineage
Figure 4.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Route of Administration
Figure 4.7 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Cardiovascular Disorder
Figure 4.8 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Metabolic Disorder
Figure 4.9 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Key Developers
Figure 4.10 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Indication and Phase of Development
Figure 4.11 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Grid Analysis
Figure 4.12 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Focus Area of Developer
Figure 4.13 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Year of Establishment of Developer
Figure 4.14 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size of Developer
Figure 4.15 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Geographical Location of Developer
Figure 4.16 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size and Geographical Location of Developer
Figure 4.17 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Mapping Regional Activity
Figure 4.18 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Logo Landscape
Figure 4.19 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Designations Awarded to Stem Cell Therapies
Figure 5.1 Unmet Needs Analysis: Overview of Methodology
Figure 5.2 Unmet Needs in Cardiovascular Disorders: Word Cloud Analysis of Data from Patient Blogs
Figure 5.3 Unmet Needs in Metabolic Disorders: Word Cloud Analysis of Data from Patient Blogs
Figure 5.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature
Figure 5.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type and Year
Figure 5.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type of Indication
Figure 5.7 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Stem Cell Lineage
Figure 5.8 Unmet Needs in Stem Cell Therapies for Cardiovascular Disorders: Word Cloud Analysis of Data from Social Media Tweets
Figure 5.9 Unmet Needs in Stem Cell Therapies for Metabolic Disorders: Word Cloud Analysis of Data from Social Media Tweets
Figure 5.10 Key Unmet Needs in Cardiovascular Disorders
Figure 5.11 Key Unmet Needs in Metabolic Disorders
Figure 6.1 Key Therapeutic Indications
Figure 6.2 Heart Failure: Types
Figure 6.3 Heart Failure: Symptoms
Figure 6.4 Heart Failure: Risk Factors
Figure 6.5 Heart Failure: Distribution of Stem Cell Therapies by Phase of Development and Type of Stem Cells
Figure 6.6 Myocardial Infarction: Risk Factors
Figure 6.7 Myocardial Infarction: Distribution by Phase of Development and Type of Stem Cells
Figure 6.8 Critical Limb Ischemia: Symptoms
Figure 6.9 Critical Limb Ischemia: Risk Factors
Figure 6.10 Critical Limb Ischemia: Distribution of Stem Cell Therapies by Phase of Development and Type of Stem Cells
Figure 6.11 Diabetes: Risk Factors
Figure 6.12 Diabetes: Currently Available Non-Insulin Therapies
Figure 6.13 Diabetes: Distribution by Phase of Development and Type of Stem Cells
Figure 7.1 Competitiveness Analysis of Companies Developing Stem Cell Therapies for Cardiovascular Disorders
Figure 7.2 Competitiveness Analysis of Companies Developing Autologous Stem Cell Therapies for Cardiovascular Disorders
Figure 7.3 Competitiveness Analysis of Companies Developing Allogenic Stem Cell Therapies for Cardiovascular Disorders
Figure 7.4 Competitiveness Analysis of Companies Developing Stem Cell Therapies for Metabolic Disorders
Figure 7.5 Competitiveness Analysis of Companies Developing Autologous Stem Cell Therapies for Metabolic Disorders
Figure 7.6 Competitiveness Analysis of Companies Developing Allogenic Stem Cell Therapies for Metabolic Disorders
Figure 8.1 Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Therapeutic Area
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership, 2012-2015 and Post 2015
Figure 8.5 Partnerships and Collaborations : Activity of Big Pharmaceutical Companies
Figure 8.6 Partnerships and Collaborations: Regional Distribution
Figure 8.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 8.8 Partnerships and Collaborations: Most Active Players
Figure 9.1 Funding and Investments: Distribution by Type of Funding and Year, 2012-2018
Figure 9.2 Funding and Investments: Cumulative Number of Instances by Year, 2012-2018
Figure 9.3 Funding and Investments: Cumulative Amount Invested by Year, 2012-2018 (USD Million)
Figure 9.4 Funding and Investments: Distribution by Type of Funding
Figure 9.5 Funding and Investments: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 9.6 Funding and Investments: Distribution of Number of Funding Instances by Year across Major Therapeutic Areas, 2012-2018
Figure 9.7 Funding and Investments: Amount Invested by Year across Major Therapeutic Areas, 2012-2018
Figure 9.8 Funding and Investments: Distribution of Number of Instances by Type of Funding, 2012-2015 and Post 2015
Figure 9.9 Funding and Investments: Amount Invested by Type of Funding, 2012-2015 and Post 2015
Figure 9.10 Funding and Investments: Amount Invested by Year of Investments in Various Type of Stem Cells, 2012-2018
Figure 9.11 Funding and Investments: Most Active Players
Figure 9.12 Funding and Investments: Most Active Investors
Figure 9.13 Funding and Investments Summary
Figure 10.1 Publications: Cumulative Trend by Year, 2013-2018
Figure 10.2 Publications: Most Popular Journals
Figure 10.3 Publications: Distribution by Type of Study
Figure 10.4 Publications: Distribution by Type of Disorder
Figure 10.5 Publications: Distribution by Type of Cardiovascular Disorders
Figure 10.6 Publications: Distribution by Type of Metabolic Disorders
Figure 10.7 Publications: Distribution by Stem Cell Lineage
Figure 10.8 Publications: Distribution of Articles Focused on Bone Marrow Derived Stem Cells by Indication
Figure 10.9 Publications: Distribution of Articles Focused on Cardiosphere Derived Stem Cells by Indication
Figure 10.10 Publications: Distribution of Articles Focused on Adipose Derived Stem Cells by Indication
Figure 10.11 Publications: Emerging Areas
Figure 11.1 Stempeucel®: History of Development
Figure 11.2 Stempeucel®: Development / Manufacturing Process
Figure 11.3 aBMC by Cesca Therapeutics: History of Development
Figure 11.4 aBMC by Cesca Therapeutics: Development / Manufacturing Process
Figure 11.5 BCDA-01: History of Development
Figure 11.6 BCDA-01: Development / Manufacturing Process
Figure 11.7 BCDA-02: History of Development
Figure 11.8 BCDA-02: Development / Manufacturing Process
Figure 11.9 CLBS14-NORDA: History of Development
Figure 11.10 CLBS14-NORDA: Development / Manufacturing Process
Figure 11.11 MPC-150-IM: History of Development
Figure 11.12 MPC-150-IM: Development / Manufacturing Process
Figure 11.13 PLX-PAD: Mechanism of Action
Figure 11.14 PLX-PAD: History of Development
Figure 11.15 PLX-PAD: Development / Manufacturing Process
Figure 12.1 Strimvelis®: History of Development
Figure 12.2 Strimvelis®: Development / Manufacturing Process
Figure 12.3 OTL-200: Development / Manufacturing Process
Figure 12.4 Unnamed Stem Cell Therapy by Global Cell Med: Development / Manufacturing Process
Figure 12.5 Stem Cell Educator System: History of Development
Figure 12.6 Stem Cell Educator System: Development / Manufacturing Process
Figure 13.1 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, 2019-2030 (USD Million)
Figure 13.2 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, 2019-2030 (USD Million)
Figure 13.3 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030 (USD Million)
Figure 13.4 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, 2019-2030 (USD Million)
Figure 13.5 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, 2019-2030 (USD Million)
Figure 13.6 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, 2019-2030 (USD Million)
Figure 13.7 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, 2019-2030 (USD Million)
Figure 13.8 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 13.9 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, 2019-2030 (USD Million)
Figure 13.10 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, 2019-2030 (USD Million)
Figure 13.11 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, 2019-2030 (USD Million)
Figure 13.12 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.13 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.14 Cardiocell®: Sales Forecast for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.15 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.16 HeartSheet®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.17 HeartSheet®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.18 BCDA-01: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.19 BCDA-01: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.20 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.21 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.22 Cardiocell®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.23 Cardiocell®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.24 MyoCell®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.25 MyoCell®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.26 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.27 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.28 aBMC by Cesca Therapeutics: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.29 aBMC by Cesca Therapeutics: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.30 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.31 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.32 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.33 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.34 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.35 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.36 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.37 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.38 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.39 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.40 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, 2019-2030 (USD Million)
Figure 13.41 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, 2019-2030 (USD Million)
Figure 13.42 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030 (USD Million)
Figure 13.43 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 13.44 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, 2019-2030 (USD Million)
Figure 13.45 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, 2019-2030 (USD Million)
Figure 13.46 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, 2019-2030 (USD Million)
Figure 13.47 Strimvelis®: Sales Forecast for ADA-SCID, Till 2030 (USD Million)
Figure 13.48 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Till 2030 (USD Million)
Figure 13.49 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Till 2030 (USD Million)
Figure 13.50 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Till 2030 (USD Million)
Figure 13.51 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Till 2030 (USD Million)
Figure 13.52 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast by Geography for Type 1 Diabetes, Till 2030 (USD Million)
Figure 14.1 Overall Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Conservative, Base and Optimistic Forecast Scenarios, 2020 and 2030 (USD Million)
List of Tables
Table 4.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Marketed and Development Pipeline (Industry Players)
Table 4.2 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Developer Overview
Table 4.3 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Information on Dose of Stem Cell Therapies
Table 4.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Information on Designations Awarded to Stem Cell Therapies
Table 4.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Other Indications Under Evaluation
Table 4.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Pipeline Overview (Academic Players)
Table 4.7 Stem Cell Therapies for Stroke
Table 5.1 Unmet Needs in Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Blog Portals
Table 6.1 Heart Failure: List of Marketed Drugs
Table 6.2 Heart Failure: List of Stem Cell Therapies
Table 6.3 Myocardial Infarction: List of Marketed Drugs
Table 6.4 Myocardial Infarction: List of Stem Cell Therapies
Table 6.5 Peripheral Arterial Diseases: List of Marketed Drugs
Table 6.6 Critical Limb Ischemia: List of Stem Cell Therapies
Table 6.7 Diabetes: Current Treatment Landscape
Table 6.8 Diabetes: List of Stem Cell Therapies
Table 8.1 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Partnerships and Collaborations, 2012-2018
Table 9.1 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Funding and Investments, 2012-2018
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 Stem Cell Therapy for Cardiovascular and Metabolic Disorders: List of Publications, 2013-2018
Table 11.1 Stempeutics: Clinical Trials
Table 11.2 aBMC by Cesca Therapeutics: Clinical Trials
Table 11.3 BCDA-01: Clinical Trials
Table 11.4 BCDA-02: Clinical Trials
Table 11.5 CLBS14-NORDA: Clinical Trials
Table 11.6 MPC-150-IM: Clinical Trials
Table 11.7 PLX-PAD: Clinical Trials
Table 12.1 Strimvelis: Clinical Trials
Table 12.2 Stem Cell Therapy by Global Cell Med: Clinical Trials
Table 12.3 LMSCs: Clinical Trials
Table 12.4 Stem Cell Educator Therapy: Clinical Trials
Table 15.1 Kadimastem: Key Highlights
Table 15.2 Xcelthera: Key Highlights
Table 16.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Therapeutic Area
Table 16.2 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Phase of Development
Table 16.3 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells
Table 16.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells
Table 16.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Stem Cell Lineage
Table 16.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Route of Administration
Table 16.7 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Cardiovascular Disorder
Table 16.8 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Metabolic Disorder
Table 16.9 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Focus Area of Developer
Table 16.10 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Year of Establishment of Developer
Table 16.11 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size of Developer
Table 16.12 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Geographical Location of Developer
Table 16.13 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature
Table 16.14 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type and Year
Table 16.15 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type of Indication
Table 16.16 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Stem Cell Lineage
Table 16.17 Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
Table 16.18 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.19 Partnerships and Collaborations: Distribution by Year of Partnership and Therapeutic Area
Table 16.20 Partnerships and Collaborations: Distribution by Type of Partnership, 2012-2015 and Post 2015
Table 16.21 Partnerships and Collaborations: Regional Distribution
Table 16.22 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 16.23 Funding and Investments: Distribution by Type of Funding and Year, 2012-2018
Table 16.24 Funding and Investments: Cumulative Number of Instances by Year, 2012-2018
Table 16.25 Funding and Investments: Cumulative Amount Invested by Year, 2012-2018 (USD Million)
Table 16.26 Funding and Investments: Distribution by Type of Funding
Table 16.27 Funding and Investments: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 16.28 Funding and Investments: Distribution of Number of Funding Instances by Year across Major Therapeutic Areas, 2012-2018
Table 16.29 Funding and Investments: Amount Invested by Year across Major Therapeutic Areas, 2012-2018
Table 16.30 Funding and Investments: Distribution of Number of Instances by Type of Funding, 2012-2015 and Post 2015
Table 16.31 Funding and Investments: Amount Invested by Type of Funding, 2012-2015 and Post 2015
Table 16.32 Funding and Investments: Amount Invested by Year of Investments in Various Type of Stem Cells, 2012-2018
Table 16.33 Publications: Cumulative Trend by Year, 2013-2018
Table 16.34 Publications: Distribution by Type of Study
Table 16.35 Publications: Distribution by Type of Disorder
Table 16.36 Publications: Distribution by Type of Cardiovascular Disorders
Table 16.37 Publications: Distribution by Type of Metabolic Disorders
Table 16.38 Publications: Distribution by Stem Cell Lineage
Table 16.39 Publications: Distribution of Articles Focused on Bone Marrow Derived Stem Cells by Indication
Table 16.40 Publications: Distribution of Articles Focused on Cardiosphere Derived Stem Cells by Indication
Table 16.41 Publications: Distribution of Articles Focused on Adipose Derived Stem Cells by Indication
Table 16.42 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Conservative Scenario, 2019-2030 (USD Million)
Table 16.43 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Base Scenario, 2019-2030 (USD Million)
Table 16.44 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.45 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Conservative Scenario, 2019-2030 (USD Million)
Table 16.46 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Base Scenario, 2019-2030 (USD Million)
Table 16.47 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.48 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.49 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.50 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.51 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 16.52 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 16.53 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.54 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Conservative Scenario, 2019-2030 (USD Million)
Table 16.55 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Base Scenario, 2019-2030 (USD Million)
Table 16.56 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.57 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Conservative Scenario, 2019-2030 (USD Million)
Table 16.58 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Base Scenario, 2019-2030 (USD Million)
Table 16.59 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.60 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.61 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.62 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.63 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Conservative Scenario, 2019-2030 (USD Million)
Table 16.64 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Base Scenario, 2019-2030 (USD Million)
Table 16.65 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.66 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.67 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.68 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.69 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Conservative Scenario, 2019-2030 (USD Million)
Table 16.70 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Base Scenario, 2019-2030 (USD Million)
Table 16.71 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.72 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 16.73 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 16.74 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.75 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.76 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.77 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.78 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.79 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.80 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.81 Cardiocell®: Sales Forecast for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.82 Cardiocell®: Sales Forecast for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.83 Cardiocell®: Sales Forecast for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.84 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.85 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.86 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.87 HeartSheet®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.88 HeartSheet®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.89 HeartSheet®: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.90 HeartSheet®: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.91 HeartSheet®: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.92 HeartSheet®: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.93 BCDA-01: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.94 BCDA-01: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.95 BCDA-01: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.96 BCDA-01: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.97 BCDA-01: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.98 BCDA-01: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.99 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.100 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.101 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.102 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.103 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.104 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.105 Cardiocell®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.106 Cardiocell®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.107 Cardiocell®: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.108 Cardiocell®: Sales Forecast by Geography for Heart Failure, Conservative Scenario Till 2030 (USD Million)
Table 16.109 Cardiocell®: Sales Forecast by Geography for Heart Failure, Base Scenario Till 2030 (USD Million)
Table 16.110 Cardiocell®: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario Till 2030 (USD Million)
Table 16.111 MyoCell®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.112 MyoCell®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.113 MyoCell®: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.114 MyoCell®: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.115 MyoCell®: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.116 MyoCell®: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.117 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.118 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.119 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.120 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.121 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.122 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.123 aBMC by Cesca Therapeutics: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.124 aBMC by Cesca Therapeutics: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.125 aBMC by Cesca Therapeutics: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.126 aBMC by Cesca Therapeutics: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.127 aBMC by Cesca Therapeutics: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.128 aBMC by Cesca Therapeutics: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.129 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.130 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.131 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.132 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.133 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.134 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.135 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.136 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.137 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.138 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.139 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.140 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.141 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.142 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.143 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.144 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.145 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, base Scenario, Till 2030 (USD Million)
Table 16.146 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.147 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.148 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.149 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.150 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.151 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.152 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.153 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.154 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.155 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.156 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.157 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.158 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.159 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Conservative Scenario, 2019-2030 (USD Million)
Table 16.160 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Base Scenario, 2019-2030 (USD Million)
Table 16.161 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.162 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Conservative Scenario, 2019-2030 (USD Million)
Table 16.163 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Base Scenario, 2019-2030 (USD Million)
Table 16.164 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.165 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.166 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.167 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.168 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Conservative Scenario, 2019-2030 (USD Million)
Table 16.169 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Base Scenario, 2019-2030 (USD Million)
Table 16.170 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.171 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.172 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.173 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.174 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Conservative Scenario, 2019-2030 (USD Million)
Table 16.175 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Base Scenario, 2019-2030 (USD Million)
Table 16.176 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.177 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 16.178 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 16.179 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.180 Strimvelis®: Sales Forecast for ADA-SCID, Conservative Scenario, Till 2030 (USD Million)
Table 16.181 Strimvelis®: Sales Forecast for ADA-SCID, Base Scenario, Till 2030 (USD Million)
Table 16.182 Strimvelis®: Sales Forecast for ADA-SCID, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.183 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Conservative Scenario, Till 2030 (USD Million)
Table 16.184 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Base Scenario, Till 2030 (USD Million)
Table 16.185 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.186 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Conservative Scenario, Till 2030 (USD Million)
Table 16.187 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Base Scenario, Till 2030 (USD Million)
Table 16.188 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.189 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Conservative Scenario, Till 2030 (USD Million)
Table 16.190 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Base Scenario, Till 2030 (USD Million)
Table 16.191 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.192 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Conservative Scenario, Till 2030 (USD Million)
Table 16.193 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Base Scenario, Till 2030 (USD Million)
Table 16.194 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.195 Unnamed Stem Cell Therapy by Global Cell Med : Sales Forecast by Geography for Type 1 Diabetes, Conservative Scenario, Till 2030 (USD Million)
Table 16.196 Unnamed Stem Cell Therapy by Global Cell Med : Sales Forecast by Geography for Type 1 Diabetes, Base Scenario, Till 2030 (USD Million)
Table 16.197 Unnamed Stem Cell Therapy by Global Cell Med : Sales Forecast by Geography for Type 1 Diabetes, Opportunistic Scenario, Till 2030 (USD Million)